Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
J Med Chem ; 44(23): 3925-31, 2001 Nov 08.
Article in English | MEDLINE | ID: mdl-11689078

ABSTRACT

A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine WR-99210 (8s), have been prepared. Several of them, such as 5b (PS-33) and 5m (PS-26), maintain or exceed the in vivo activity of PS-15 while not requiring the use of highly regulated starting materials. The putative diaminotriazine metabolites of these new analogues (compounds 8) have also been prepared and shown to maintain the activity against resistant P. falciparum strains. The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.


Subject(s)
Antimalarials/chemical synthesis , Folic Acid Antagonists/chemical synthesis , Guanidines/chemical synthesis , Prodrugs/chemical synthesis , Proguanil/analogs & derivatives , Proguanil/chemical synthesis , Tetrahydrofolate Dehydrogenase/metabolism , Triazines/chemical synthesis , Animals , Antimalarials/chemistry , Antimalarials/pharmacology , Antimalarials/toxicity , Drug Evaluation, Preclinical , Female , Folic Acid Antagonists/chemistry , Folic Acid Antagonists/pharmacology , Folic Acid Antagonists/toxicity , Guanidines/chemistry , Guanidines/pharmacology , Guanidines/toxicity , Malaria/drug therapy , Male , Mice , Plasmodium berghei , Plasmodium falciparum/drug effects , Prodrugs/chemistry , Prodrugs/pharmacology , Prodrugs/toxicity , Proguanil/chemistry , Proguanil/pharmacology , Proguanil/toxicity , Structure-Activity Relationship , Triazines/chemistry , Triazines/pharmacology , Triazines/toxicity
2.
Braz J Infect Dis ; 5(2): 67-72, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11493411

ABSTRACT

The efficacy and safety of a fixed-dose combination of atovaquone and proguanil hydrochloride (Malarone) were compared with chloroquine or pyrimethamine/sulfadoxine in patients with acute falciparum malaria in northern Peru. Patients were initially randomized to receive 1,000 mg atovaquone and 400 mg proguanil hydrochloride daily for 3 days (n=15) or 1,500 mg chloroquine (base) over a 3 day period (n=14) (phase 1). The cure rate with chloroquine was lower than expected and patients were subsequently randomized to receive a single dose of 75 mg pyrimethamine and 1,500 mg sulfadoxine (n=9) or atovaquone/proguanil as before (n=5) (phase 2). In phase 1, atovaquone/proguanil was significantly more effective than chloroquine (cure rate 100% [14/14] vs. 8% [1/13], P<0.0001). In phase 2, atovaquone/proguanil and pyrimethamine/sulfadoxine were both highly effective (cure rates 100% [5/5] and 100% [7/7]). There were no significant differences between treatment groups in parasite or fever clearance times. Adverse events were typical of malarial symptoms and did not differ significantly between groups. Overall efficacy of atovaquone/proguanil was 100% for treatment of acute falciparum malaria in a region with a high prevalence of chloroquine resistance.


Subject(s)
Antimalarials/therapeutic use , Chloroquine/therapeutic use , Malaria, Falciparum/drug therapy , Naphthoquinones/therapeutic use , Proguanil/therapeutic use , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Adolescent , Adult , Aged , Animals , Antimalarials/adverse effects , Atovaquone , Chloroquine/adverse effects , Drug Combinations , Drug Resistance, Microbial , Drug Therapy, Combination , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Naphthoquinones/adverse effects , Peru , Proguanil/adverse effects , Pyrimethamine/adverse effects , Sulfadoxine/adverse effects , Treatment Outcome
3.
Braz. j. infect. dis ; 5(2): 67-72, Apr. 2001. tab
Article in English | LILACS | ID: lil-301186

ABSTRACT

The efficacy and safety of a fixed-dose combination of atovaquone and proguanil hydrochloride (Malarone TM) were compared with chloroquine or pyrimethamine/sulfadoxine in patients with acute falciparum malaria in northern Peru. Patients were initially randomized to receive, 1,000 mg atovaquone and 400 mg mg proguanil hydrochloride daily for 3 days (n=15) or 1,500 mg chloroquine (base) over a 3 day period (n=14) (phase 1). The cure rate with chloroquine was lower than expected and patients were subsequently randomized to receive a single dose of 75 mg pyrimethamine and 1,500 mg sulfadoxine (n=9) or atovaquone/proguanil as before (n=5) (phase 2). In phase 1, atovaquone/proguanil was significantly more effective than chloriquine (cure rate 100 percent [14/14] versus 8 percent [1/13], P<0.0001). In phase 2, atovaquone/proguanil and pyrimethamine/sulfadoxine were both highly effective (cure rates 100 percent [5/5] and 100 percent [7/7]). There were no significant differences between treatment groups in parasite or fever clearance times. Adverse events were typical of malarium symptoms and did not differ significantly between groups. Overall efficacy of atovaquone/proguanil was 100 percent for treatment of acute falciparum malaria in a region with a high prevalence of chloroquine resistance.


Subject(s)
Humans , Adolescent , Adult , Middle Aged , Chloroquine , Malaria, Falciparum , Plasmodium falciparum , Proguanil , Pyrimethamine , Sulfadoxine , Acute Disease , Antimalarials , Clinical Trials, Phase II as Topic , Clinical Trials, Phase I as Topic , Malaria, Falciparum , Drug Resistance, Microbial
4.
Clin Ther ; 21(5): 841-52, 1999 May.
Article in English | MEDLINE | ID: mdl-10397379

ABSTRACT

Atovaquone and proguanil hydrochloride are blood schizonticides that demonstrate in vitro synergy against drug-resistant strains of Plasmodium falciparum. When coadministered, they may therefore be effective for the treatment of malaria in regions where there is known or suspected drug resistance. In an open-label, randomized, parallel-group, clinical trial conducted in Zambia, 163 patients (age range, 14 to 54 years) with acute P falciparum malaria were randomly assigned to receive treatment with atovaquone and proguanil hydrochloride (1000 and 400 mg, respectively, administered orally at 24-hour intervals for 3 doses; n = 82) or pyrimethamine/sulfadoxine (75/1500 mg administered orally as a single dose; n = 81). Efficacy was assessed by cure rate (the percentage of patients in whom parasitemia was eliminated and did not recur during 28 days of follow-up), parasite clearance time (PCT), and fever clearance time (FCT). Safety was determined by sequential clinical and laboratory assessments over 28 days. Cure rates did not differ significantly between patients treated with atovaquone and proguanil (100%) and those treated with pyrimethamine/sulfadoxine (98.8%). Patients in the atovaquone and proguanil group had a significantly shorter FCT than patients in the pyrimethamine/sulfadoxine group (mean, 30.4 vs 44.9 hours; P < 0.05) but a longer PCT (mean, 64.0 vs 51.4 hours; P < 0.05). Both treatments were well tolerated; adverse events and laboratory abnormalities were typical of those normally observed in patients with malaria. In this study, the combination of atovaquone and proguanil was equally effective and as well tolerated as pyrimethamine/sulfadoxine for the treatment of acute, uncomplicated, drug-resistant falciparum malaria in Zambia.


Subject(s)
Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Proguanil/therapeutic use , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Adolescent , Adult , Animals , Blood Cells/drug effects , Blood Cells/parasitology , Blood Chemical Analysis , Female , Humans , Male , Middle Aged , Polypharmacy , Pyrimethamine/adverse effects , Sulfadoxine/adverse effects , Zambia
5.
Pediatr Infect Dis J ; 18(5): 456-61, 1999 May.
Article in English | MEDLINE | ID: mdl-10353520

ABSTRACT

BACKGROUND: Malaria is a major cause of pediatric mortality in sub-Saharan Africa. Worldwide estimates of mortality among children with Plasmodium falciparum malaria range from 1 to 2 million deaths per year. Management of malaria is increasingly difficult because of the global spread of drug-resistant strains of P. falciparum. There is an urgent need for safe and effective new therapies to treat multidrug-resistant malaria. METHODS: This open label, randomized trial compared atovaquone and proguanil hydrochloride with halofantrine for treatment of acute, uncomplicated P. falciparum malaria in children age 3 to 12 years (84 patients per group). Study drug dosages were adjusted by weight (approximately 20 and 8 mg/kg daily for three doses for atovaquone and proguanil hydrochloride and 8 mg/kg every 6 h for three doses for halofantrine). Patients were monitored by serial clinical and laboratory assessments for 28 days after starting treatment. RESULTS: Both regimens were effective (cure rate, 93.8% for atovaquone and proguanil hydrochloride and 90.4% for halofantrine) and produced prompt defervescence. Mean parasite clearance times were 50.2 h for halofantrine and 64.9 h for atovaquone and proguanil hydrochloride. More adverse experiences were reported in children treated with halofantrine (119) than with atovaquone and proguanil hydrochloride (73). CONCLUSIONS: In Kenyan children the combination of atovaquone and proguanil hydrochloride has efficacy comparable with that of halofantrine for treatment of acute uncomplicated multidrug-resistant falciparum malaria and is associated with a lower rate of adverse events.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Naphthoquinones/therapeutic use , Phenanthrenes/therapeutic use , Proguanil/therapeutic use , Acute Disease , Animals , Atovaquone , Child , Child, Preschool , Drug Therapy, Combination , Feces/parasitology , Female , Humans , Male , Plasmodium falciparum/isolation & purification , Treatment Outcome
6.
J Infect Dis ; 179(6): 1587-90, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10228090

ABSTRACT

This randomized, open-label clinical trial compared a fixed-dose combination of atovaquone and proguanil (n=55) with chloroquine (n=23) or a combination of chloroquine, sulfadoxine, and pyrimethamine (n=32) for treatment of acute falciparum malaria in the Philippines. Patients were hospitalized for 28 days to ensure medication compliance and prevent reinfection. Atovaquone-proguanil produced a significantly higher cure rate (100%) compared with that for chloroquine (30.4%; P<.0001) or chloroquine-sulfadoxine-pyrimethamine (87.5%; P<.05). Treatments did not differ significantly with respect to parasite clearance time (mean: 46.7 h for atovaquone-proguanil, 60.0 h for chloroquine, and 42.8 h for chloroquine-sulfadoxine-pyrimethamine) or fever clearance time (mean, 38.8, 46.8, and 34.5 h, respectively). Adverse events were typical of malaria symptoms; the most frequently reported events were vomiting (18% for atovaquone-proguanil, 17% for chloroquine, and 9% for chloroquine-sulfadoxine-pyrimethamine), abdominal pain (15%, 17%, and 3%, respectively), anorexia (11%, 13%, and 0%, respectively), and headache (6%, 17%, and 3%, respectively). Atovaquone-proguanil was well tolerated and more effective than chloroquine or chloroquine-sulfadoxine-pyrimethamine for treatment of multidrug-resistant falciparum malaria in the Philippines.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Naphthoquinones/therapeutic use , Proguanil/therapeutic use , Atovaquone , Chloroquine/therapeutic use , Drug Therapy, Combination , Folic Acid Antagonists/therapeutic use , Humans , Philippines , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use
7.
Am J Trop Med Hyg ; 60(4): 526-32, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10348224

ABSTRACT

The increasing frequency of therapeutic failures in falciparum malaria underscores the need for novel, rapidly effective antimalarial drugs or drug combinations. Atovaquone and proguanil are blood schizonticides that demonstrate synergistic activity against multi-drug-resistant Plasmodium falciparum in vitro. In an open-label, randomized, controlled clinical trial conducted in Thailand, adult patients with acute P. falciparum malaria were randomly assigned to treatment with atovaquone and proguanil/hydrochloride (1,000 mg and 400 mg, respectively, administered orally at 24-hr intervals for three doses) or mefloquine (750 mg administered orally, followed 6 hr later by an additional 500-mg dose). Efficacy was assessed by cure rate (the percentage of patients in whom parasitemia was eliminated and did not recur during 28 days of follow-up), parasite clearance time (PCT), and fever clearance time (FCT). Safety was assessed by sequential clinical and laboratory assessments for 28 days. Atovaquone/proguanil was significantly more effective than mefloquine (cure rate 100% [79 of 79] vs. 86% [68 of 79]; P < 0.002). The atovaquone/proguanil and mefloquine treatments did not differ with respect to PCT (mean = 65 hr versus 74 hr) or FCT (mean = 59 hr versus 51 hr). Adverse events were generally typical of malaria symptoms and each occurred in < 10% of the patients in either group, with the exception of increased vomiting found in the atovaquone/proguanil group. Transient elevations of liver enzyme levels occurred more frequently in patients treated with atovaquone/proguanil than with mefloquine, but the differences were not significant and values returned to normal by day 28 in most patients. The combination of atovaquone and proguanil was well tolerated and more effective than mefloquine in the treatment of acute uncomplicated multidrug-resistant falciparum malaria in Thailand.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Naphthoquinones/therapeutic use , Proguanil/therapeutic use , Acute Disease , Adolescent , Adult , Antimalarials/adverse effects , Atovaquone , Drug Combinations , Female , Humans , Malaria, Falciparum/blood , Male , Mefloquine/adverse effects , Middle Aged , Naphthoquinones/adverse effects , Proguanil/adverse effects , Thailand , Treatment Outcome
8.
Am J Trop Med Hyg ; 60(4): 533-41, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10348225

ABSTRACT

The continuing spread of drug-resistant malaria emphasizes the need for new antimalarial drugs. Atovaquone is a broad-spectrum antiprotozoal drug with a novel mechanism of action, via inhibition of parasite mitochondrial electron transport, and a favorable safety profile. Early studies with atovaquone alone for treatment of malaria demonstrated good initial control of parasitemia but an unacceptable rate of recrudescent parasitemia. Parasites isolated during recrudescence after treatment with atovaquone alone were resistant to atovaquone in vitro. The combination of atovaquone and proguanil is synergistic in vitro, and clinical studies demonstrated enhanced efficacy of the combination compared to either drug alone for treatment of malaria. Malarone, a fixed-dose combination of 250 mg of atovaquone and 100 mg of proguanil hydrochloride, is available in many countries for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum. At the recommended dose (in adults, four tablets once a day for three days), the overall cure rate was > 98% in more than 500 patients with falciparum malaria. In four randomized, controlled clinical trials, treatment with atovaquone and proguanil hydrochloride was significantly more effective than mefloquine (Thailand), amodiaquine (Gabon), chloroquine (Peru and the Philippines) or chloroquine plus pyrimethamine/sulfadoxine (Philippines). In clinical trials where the comparator drug was highly effective, treatment with atovaquone and proguanil hydrochloride was equally effective. Parasites isolated during recrudescence after treatment with the combination of atovaquone and proguanil were not resistant to atovaquone in vitro. The most commonly reported adverse events in clinical trials (abdominal pain, anorexia, nausea, vomiting, diarrhea and coughing) occurred with similar frequency in patients treated with a comparator drug. Malarone is a safe and effective new agent for treatment of malaria.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Naphthoquinones/therapeutic use , Proguanil/therapeutic use , Adult , Aged , Antimalarials/administration & dosage , Antimalarials/adverse effects , Atovaquone , Child , Drug Combinations , Drug Therapy, Combination , Humans , Naphthoquinones/administration & dosage , Naphthoquinones/adverse effects , Proguanil/administration & dosage , Proguanil/adverse effects , Randomized Controlled Trials as Topic
9.
Trans R Soc Trop Med Hyg ; 92(2): 201-6, 1998.
Article in English | MEDLINE | ID: mdl-9764334

ABSTRACT

A trial was conducted in 32 Thai children with uncomplicated multidrug-resistant falciparum malaria to assess the efficacy, safety and pharmacokinetics of atovaquone and proguanil; plasma concentrations of atovaquone, proguanil and its metabolite, cycloguanil, were measured in a subset of 9 children. The children received atovaquone (17 mg/kg/d for 3 d) plus proguanil (7 mg/kg/d for 3 d). Twenty-six children who had only Plasmodium falciparum infection and remained in hospital for 28 d were assessed for drug efficacy. The combination regimen produced a cure rate of 100%. Parasite and fever clearance times were 47 h (range 8-75) and 50 h (range 7-111), respectively. Atovaquone and proguanil were rapidly absorbed, with median time to peak concentrations of 6 h (range 6-24) and 6 h (range 6-12), respectively. Peak concentrations of cycloguanil were achieved between 6 and 12 h (median 6) after administration of proguanil. Mean peak plasma concentration of atovaquone on day 3 was 5.1 micrograms/mL (SD = 2.1). The day 3 mean peak plasma concentration of proguanil was 306 ng/mL (SD = 108) compared with 44.3 ng/mL (SD = 27.3) for cycloguanil. Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil. Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively. No major adverse effect was attributable to the study drugs. Atovaquone/proguanil combination is safe and highly effective, and should be especially valuable for treatment of multidrug-resistant falciparum malaria.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Naphthoquinones/therapeutic use , Parasitemia/drug therapy , Proguanil/therapeutic use , Antimalarials/pharmacokinetics , Atovaquone , Child , Drug Resistance, Multiple , Drug Therapy, Combination , Female , Humans , Malaria, Falciparum/metabolism , Male , Naphthoquinones/pharmacokinetics , Proguanil/pharmacokinetics , Prospective Studies , Triazines/pharmacokinetics
10.
Clin Pharmacol Ther ; 61(5): 518-30, 1997 May.
Article in English | MEDLINE | ID: mdl-9164414

ABSTRACT

The population pharmacokinetics of atovaquone were examined in 458 black, Oriental, and Malay patients with acute Plasmodium falciparum malaria receiving atovaquone alone or concomitantly with other drugs. Oral clearance (CL/F) showed a 0.674 power relationship with weight and is similar in Oriental and Malay subjects but 58.5% lower in black subjects. On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively. The relationship between apparent volume of distribution (V area/F) and weight was linear and similar in all three races at 7.98 L/kg. The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively. The bioavailability of the high and low doses of atovaquone was similar. Neither CL/F nor V area/F were significantly affected by age, gender, and the coadministration with chloroguanide (proguanil), pyrimethamine, and tetracycline. Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively. The final magnitudes of interpatient variability in CL/F and V area/F were 68% and 49%, respectively.


Subject(s)
Antimalarials/pharmacokinetics , Malaria, Falciparum/drug therapy , Naphthoquinones/pharmacokinetics , Adolescent , Adult , Analysis of Variance , Antimalarials/blood , Antimalarials/therapeutic use , Atovaquone , Child , Child, Preschool , Computer Simulation , Databases, Factual , Dose-Response Relationship, Drug , Female , Gabon , Humans , Kenya , Malaria, Falciparum/blood , Malaria, Falciparum/metabolism , Male , Middle Aged , Models, Biological , Naphthoquinones/blood , Naphthoquinones/therapeutic use , Philippines , Thailand , Zambia
11.
Br J Clin Pharmacol ; 42(5): 589-97, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8951190

ABSTRACT

1. The pharmacokinetics of proguanil were evaluated in patients with acute P. falciparum malaria receiving concomitantly proguanil hydrochloride and atovaquone. The population consisted of 203 Blacks, 112 Orientals and 55 Malays; 274 males and 96 females. Of the 370 patients, 114 and 256 patients were classified as 'poor' and 'extensive' metabolizers of proguanil, respectively. Body weight and age ranged between 11-110 kg and 3-65 years, respectively. 2. A one compartment model with first-order absorption and elimination was fitted to proguanil plasma concentration-time profiles, using non-linear mixed effect modelling (NONMEM). 3. Oral clearance (CLo) showed a 0.785 power relationship with body weight and was 13% higher in Orientals than Blacks and Malays and 17% lower in 'poor' than 'extensive' metabolizers. According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively. Age, gender and dose had no significant effects on CLo. 4. Apparent volume of distribution (V/F) showed a 0.88 power relationship with body weight. The final population estimates were 562 and 1629 l in children (< or = 15 years) and patients aged > 15 years, respectively, who had a mean body weight of 22.6 and 54.8 kg, respectively. The effect of other covariates on V/F was not examined. 5. The final magnitudes of interpatient variability in CLo and V/F were relatively low at 22.5 and 17.0%, respectively. 6. Population pharmacokinetic parameter estimates in Black, Oriental and Malay patients with acute P. falciparum malaria are in good agreement with results of pharmacokinetic studies in healthy Caucasian volunteers. In view of the 30-50% residual variability in proguanil plasma concentrations, the slight effects of Orientals and 'poor' metabolizers on CLo are unlikely to be clinically significant. Hence, dose recommendation will be solely based on body weight.


Subject(s)
Antimalarials/pharmacokinetics , Malaria, Falciparum/drug therapy , Naphthoquinones/administration & dosage , Proguanil/pharmacokinetics , Acute Disease , Adolescent , Adult , Aged , Antimalarials/administration & dosage , Atovaquone , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Proguanil/administration & dosage
12.
Am J Trop Med Hyg ; 54(1): 62-6, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8651372

ABSTRACT

The therapy of Plasmodium falciparum malaria continues to be a problem in many parts of Southeast Asia because of multidrug resistance to nearly all existing antimalarial drugs. Atovaquone is a novel hydroxynaphthoquinone with broad spectrum anti-protozoal activity. We recently evaluated the antimalarial activity of atovaquone in a series of dose-ranging studies in 317 patients with malaria at the Bangkok Hospital for Tropical Diseases. Originally, the drug was administered alone. Using atovaquone alone resulted in satisfactory, initial clinical responses in all patients; the mean parasite and fever clearance times were 62 and 53 hr, respectively. However, irrespective of the duration of therapy, overall cure rates were approximately 67%. In vitro sensitivity studies on parasites taken from patients prior to treatment and at the time of recrudescence showed a marked decrease in susceptibility to atovaquone in the recrudescent parasites. To improve cure rates, atovaquone was administered in combination with other drugs with antimalarial activity. Proguanil and tetracycline were chosen due to laboratory evidence of potentiation; doxycycline was selected because it has a longer half-life than tetracycline. Although pyrimethamine did not show laboratory evidence of potentiation with atovaquone, it was chosen as an alternative inhibitor of dihydrofolic acid reductase with a longer half-life than proguanil. The clinical studies with these drug combinations confirmed the laboratory results with marked improvement in cure rates for proguanil, tetracycline, and doxycycline; pyrimethamine showed only minimal improvement. Proguanil was subsequently selected as the preferred drug partner because of its long record of safety and the ability to use the drug in pregnant women and children. Of the 104 patients with falciparum malaria treated with atovaquone plus proguanil for 3-7 days, 101 were cured and had virtually no adverse side effects. The combination of atovaquone and proguanil also was effective in eliminating erythrocytic forms of P. vivax, but parasitemia recurred in most patients.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Naphthoquinones/therapeutic use , Acute Disease , Adolescent , Adult , Aged , Atovaquone , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Naphthoquinones/administration & dosage
13.
Exp Parasitol ; 80(3): 373-81, 1995 May.
Article in English | MEDLINE | ID: mdl-7729473

ABSTRACT

A series of Plasmodium falciparum in vitro drug sensitivity studies were conducted in order to evaluate atovaquone in combination with other antimalarial drugs and thus to identify a potential partner for a fixed combination. The derived isobolograms indicated that drug interactions ranged from antagonism through addition to synergy. Of particular note were the quinolines and artemisinin analogues, which were all antagonistic, and the biguanides and tetracycline, which showed synergy. Proguanil emerged as the most promising of the current antimalarials as a partner for atovaquone in a fixed combination, with tetracycline as back-up.


Subject(s)
Antimalarials/pharmacology , Artemisinins , Naphthoquinones/pharmacology , Plasmodium falciparum/drug effects , Animals , Atovaquone , Drug Interactions , Lactones/pharmacology , Proguanil/pharmacology , Quinolines/pharmacology , Sesquiterpenes/pharmacology , Tetracycline/pharmacology
14.
Am J Trop Med Hyg ; 50(6): 784-9, 1994 Jun.
Article in English | MEDLINE | ID: mdl-8024075

ABSTRACT

One hundred nine adult patients with acute uncomplicated falciparum malaria were randomly selected to receive combinations of either doxycycline plus mefloquine or doxycycline plus artesunate. Fifty-four patients received mefloquine (1,250 mg divided between two doses of 750 and 500 mg six hours apart) with doxycycline and 55 patients received artesunate (300 mg total for 2.5 days; 100 mg followed by 50 mg every 12 hr for 2.5 days) with doxycycline. Doxycycline was administered in doses of 200 mg once a day for seven days. All patients were admitted to the hospital for 28 days to exclude reinfection. Ninety-seven patients completed the study; 12 patients left prior to completion of follow-up for reasons unrelated to their treatment. Cure rates for the two groups were 96% (46 of 48) for mefloquine plus doxycycline and 80% (39 of 49) for artesunate plus doxycycline. Mean fever and parasite clearance times were significantly shorter in the group that received artesunate plus doxycycline (38.7 and 41.3 hr) than mefloquine plus doxycycline (64.3 and 69.0 hr), respectively. In vitro drug sensitivity testing of selected isolates obtained prior to treatment indicated that eight of nine admission isolates were resistant to mefloquine; all isolates were susceptible to artesunate. Recrudescent isolates failed to show a pattern of decreased sensitivity to the drugs to which the parasites had been exposed during treatment; the studies showed decreased sensitivity to doxycycline in only two of eight isolates tested.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Artemisinins , Doxycycline/therapeutic use , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Acute Disease , Adolescent , Adult , Animals , Antimalarials/administration & dosage , Antimalarials/adverse effects , Antimalarials/therapeutic use , Artesunate , Doxycycline/administration & dosage , Doxycycline/adverse effects , Drug Resistance , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Mefloquine/administration & dosage , Mefloquine/adverse effects , Middle Aged , Plasmodium falciparum/drug effects , Plasmodium falciparum/isolation & purification , Recurrence , Sesquiterpenes/administration & dosage , Sesquiterpenes/adverse effects , Sesquiterpenes/therapeutic use
15.
Ann Intern Med ; 120(4): 294-9, 1994 Feb 15.
Article in English | MEDLINE | ID: mdl-8291822

ABSTRACT

OBJECTIVE: To determine whether doxycycline, 100 mg administered as a single daily oral dose, is effective as a causal prophylactic agent, an agent active against the pre-erythrocytic liver stage of Plasmodium falciparum malaria parasites, in healthy nonimmune persons. If effective, the recommendation by the Centers for Disease Control and Prevention (CDC) that doxycycline be continued for 4 weeks after returning from malaria-endemic areas could be shortened to 1 week. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Medical ward at the U.S. Army Research Institute of Infectious Diseases, Fort Detrick, Maryland. PARTICIPANTS: 18 nonimmune, healthy, adult male volunteers, age 21.7 +/- 2.9 (SD) years, were enrolled in two groups, one of 8 persons and one of 10 persons. Six participants in the first group and 7 in the second group received doxycycline. The remaining participants received placebo. Two volunteers were dropped from the study, leaving 16 participants for analysis. INTERVENTION: Each participant received doxycycline, 100 mg, or placebo in a single daily oral dose starting 3 days before exposure to P. falciparum-infected mosquitoes and ending 6 days after exposure. MEASUREMENTS: Monitoring for parasitemia, plasma doxycycline concentrations, and mosquitoes' salivary-gland sporozoite grade. RESULTS: 6 of 6 (100% [95% Cl, 54% to 100%]) participants on doxycycline in the first group and 2 of 6 (33% [Cl, 4% to 78%]) in the second group were protected from malaria. No differences were found between protected and nonprotected participants in the doxycycline elimination half-life (T1/2) (20.8 +/- 5.0 h compared with 21.9 +/- 5.2 h), the steady-state average plasma concentration (1626 +/- 469 ng/mL compared with 1698 +/- 651 ng/mL), or other pharmacokinetic parameter estimates. The mean mosquito salivary-gland sporozoite grade was significantly higher (P = 0.02) in protected (3.5 +/- 0.3) than in nonprotected persons (3.1 +/- 0.1). Overall, 8 of 12 persons on doxycycline were protected from malaria, yielding a causal prophylactic efficacy rate of 67% (Cl, 35% to 90%). CONCLUSIONS: A dosing regimen of doxycycline, 100 mg once daily, administered as a causal prophylactic agent against P. falciparum malaria in healthy, nonimmune volunteers, had an unacceptably high failure rate. Therefore, the CDC recommendation that doxycycline should be taken daily starting 1 to 2 days before travel, during travel, and for 4 weeks after travel should still be followed.


Subject(s)
Doxycycline/administration & dosage , Malaria, Falciparum/prevention & control , Administration, Oral , Adult , Animals , Double-Blind Method , Doxycycline/pharmacokinetics , Drug Administration Schedule , Humans , Immunocompetence , Male
16.
Am J Trop Med Hyg ; 49(1): 121-6, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8352384

ABSTRACT

A new, orally-active inhibitor of dihydrofolic acid reductase (DHFR), PS-15 (N-(3-(2,4,5-trichlorophenoxy)propyloxy)-N'-(1-methylethyl)- imidocarbonimidic diamide hydrochloride), has significant activity against drug-resistant Plasmodium falciparum. It is not cross-resistant with other inhibitors of DHFR (e.g., pyrimethamine and cycloguanil). Although it bears similarities to proguanil, PS-15 represents a new antifolate class of drugs that we have named oxyguanils or hydroxylamine-derived biguanides. This compound displays intrinsic antimalarial activity and also is metabolized in vivo to WR99210, an extremely active triazine inhibitor of DHFR. When tested in vitro against drug-resistant clones of P. falciparum, PS-15 was more active than proguanil, and the putative metabolite, WR99210, was more active than the proguanil metabolite cycloguanil. The drug is also more active as well as less toxic than proguanil when administered orally to mice infected with P. berghei. When administered orally to Aotus monkeys infected with multidrug-resistant P. falciparum, PS-15 was more active than either proguanil or WR99210. In 1973, WR99210 underwent clinical trials for safety and tolerance in volunteers. The trials showed gastrointestinal intolerance and limited bioavailability; further development of the drug was abandoned. Because PS-15 has intrinsic antimalarial activity, is not cross-resistant with other DHFR inhibitors, and can be metabolized to WR99210 in vivo, oral administration of this new drug should circumvent the shortcomings and retain the advantages found with both proguanil and WR99210.


Subject(s)
Antimalarials/pharmacology , Folic Acid Antagonists , Imides/pharmacology , Malaria, Falciparum/drug therapy , Phenyl Ethers/pharmacology , Plasmodium falciparum/drug effects , Administration, Oral , Animals , Antimalarials/administration & dosage , Antimalarials/therapeutic use , Aotus trivirgatus , Atovaquone , Drug Synergism , Imides/administration & dosage , Imides/therapeutic use , Injections, Subcutaneous , Mice , Naphthoquinones/pharmacology , Phenyl Ethers/administration & dosage , Phenyl Ethers/therapeutic use , Proguanil/pharmacology , Proguanil/therapeutic use , Sulfamethoxazole/pharmacology , Triazines/administration & dosage , Triazines/pharmacology , Triazines/therapeutic use
17.
Am J Trop Med Hyg ; 48(3): 377-84, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8470775

ABSTRACT

The antimalarial activity of beta-artemether and beta-arteether was compared in three test systems: in vitro against chloroquine-resistant and chloroquine-sensitive Plasmodium falciparum parasites, in mice infected with P. berghei, and in Aotus monkeys infected with chloroquine-resistant P. falciparum. In vitro, the mean 50% inhibitory concentration (IC50) for beta-artemether was 1.74 nM (range 1.34-1.81 nM), and this value for beta-arteether was 1.61 nM (range 1.57-1.92 nM). They were approximately 2.5-fold more potent than artemisinin, which had a mean IC50 of 4.11 nM (range 3.36-4.60 nM). In the mouse model, the 50% curative doses (CD50) of beta-artemether and beta-arteether had a mean value of 55 mg/kg (32-78 mg/kg). The 50% effective curative doses (ED50) in the Aotus monkey were 7.1 mg/kg (95% confidence interval [CI] = 3.7-13.5) for beta-artemether and 11.8 mg/kg (95% CI = 6.5-21.3) for beta-arteether. Overall, the activities of the two drugs were comparable.


Subject(s)
Antimalarials/pharmacology , Artemisinins , Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Sesquiterpenes/pharmacology , Animals , Antimalarials/therapeutic use , Aotus trivirgatus , Artemether , Chloroquine/pharmacology , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Malaria/drug therapy , Male , Mefloquine/pharmacology , Mice , Plasmodium berghei/drug effects , Sesquiterpenes/chemistry , Sesquiterpenes/therapeutic use , Structure-Activity Relationship
18.
Am J Trop Med Hyg ; 47(6): 794-9, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1471736

ABSTRACT

A sequential combination of artesunate followed by mefloquine was evaluated prospectively in 24 patients with acute recrudescent falciparum malaria. The sequential combination was used to minimize possible side effects and to take advantage of the ability of artesunate to rapidly clear parasitemia and the prolonged effect of mefloquine to clear residual parasites. All patients had experienced one or more treatment failures with one or more courses of the following drugs (administered alone or in combination): quinine, tetracycline, mefloquine, artesunate, and sulfadoxine/pyrimethamine. Sequential treatment with artesunate (600 mg over five days) followed by mefloquine (750 mg and 500 mg six hours apart) cured all 24 patients. Each patient was followed for 28 days and 10 were observed for at least 35 days without clinical or parasitologic evidence of recrudescence. Fever and parasite clearance times after treatment with the sequential combination were 32.8 +/- 19.3 hr (mean +/- SD) and 40.0 +/- 16.2 hr, respectively. Susceptibility testing of selected parasite isolates indicated that all of the isolates tested were resistant to one or more antimalarial drugs. These results suggest that sequential treatment with artesunate followed by mefloquine is effective and well-tolerated in patients with recrudescent falciparum malaria.


Subject(s)
Antimalarials/therapeutic use , Artemisinins , Malaria, Falciparum/drug therapy , Mefloquine/therapeutic use , Sesquiterpenes/therapeutic use , Acute Disease , Adult , Animals , Antimalarials/administration & dosage , Antimalarials/pharmacology , Artesunate , Drug Administration Schedule , Drug Synergism , Drug Therapy, Combination , Female , Humans , Male , Mefloquine/administration & dosage , Mefloquine/pharmacology , Plasmodium falciparum/drug effects , Prospective Studies , Recurrence , Sesquiterpenes/administration & dosage , Sesquiterpenes/pharmacology
19.
Bull World Health Organ ; 67(1): 51-8, 1989.
Article in English | MEDLINE | ID: mdl-2706727

ABSTRACT

The effects of three separate antimalarial prophylactic regimens (proguanil, sulfisoxazole, and proguanil plus sulfisoxazole) and of vitamins in a control group were compared in a study population of 380 children living in a malaria endemic area along the Thai-Burmese border. The subjects, aged 5-16 years, were matched for age, weight, and presence of splenomegaly, then randomly assigned to one of the four groups. All medications were administered daily by the investigators and malaria smears were performed on a weekly basis. Among 99 subjects taking proguanil plus sulfisoxazole for a total of 1464 man-weeks, there was only one case of falciparum and no vivax malaria. Statistically, this regimen proved superior to each of the other groups against both Plasmodium falciparum and P. vivax. The data show that proguanil alone, as a causal or suppressive prophylatic, has poor efficacy against P. falciparum. Side-effects were infrequent and generally mild, except for two subjects whose sulfisoxazole prophylaxis was discontinued because of urticarial rash.


Subject(s)
Antimalarials/administration & dosage , Malaria/prevention & control , Proguanil/administration & dosage , Sulfisoxazole/administration & dosage , Adolescent , Child , Child, Preschool , Drug Therapy, Combination , Humans , Proguanil/adverse effects , Prospective Studies , Sulfisoxazole/adverse effects , Thailand
SELECTION OF CITATIONS
SEARCH DETAIL
...